Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Addex Therapeutics (ADXN) EBITDA (2022 - 2025)

Historic EBITDA for Addex Therapeutics (ADXN) over the last 4 years, with Q3 2025 value amounting to -$870270.5.

  • Addex Therapeutics' EBITDA fell 2118.28% to -$870270.5 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.5 million, marking a year-over-year increase of 1747.23%. This contributed to the annual value of -$2.9 million for FY2024, which is 1724.84% down from last year.
  • According to the latest figures from Q3 2025, Addex Therapeutics' EBITDA is -$870270.5, which was down 2118.28% from -$885260.4 recorded in Q2 2025.
  • Over the past 5 years, Addex Therapeutics' EBITDA peaked at -$718146.7 during Q3 2024, and registered a low of -$21.3 million during Q4 2022.
  • Moreover, its 4-year median value for EBITDA was -$3.0 million (2023), whereas its average is -$4.1 million.
  • Its EBITDA has fluctuated over the past 5 years, first surged by 8812.85% in 2023, then plummeted by 3631.51% in 2024.
  • Over the past 4 years, Addex Therapeutics' EBITDA (Quarter) stood at -$21.3 million in 2022, then soared by 88.13% to -$2.5 million in 2023, then decreased by 24.37% to -$3.1 million in 2024, then skyrocketed by 72.33% to -$870270.5 in 2025.
  • Its EBITDA stands at -$870270.5 for Q3 2025, versus -$885260.4 for Q2 2025 and -$1.6 million for Q1 2025.